Amiloidózis: vizsgálatok itt: Franciaország
32 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.
- No phaseTaking peopleQuantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis
- Where
- Caen, Lille
- Életkor
- 18 év to 100 év
- People
- 35
- Run by
- University Hospital, Caen
See details and how to joinNCT04535349 - 3. fázisTaking peopleMAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- Where
- Creteil, Marseille, Paris Cedex 18, Rennes, Toulouse Cedex 9
- Életkor
- 18 év to 90 év
- People
- 1200 worldwide
- Run by
- Intellia Therapeutics
See details and how to joinNCT06128629 · EU 2023-507220-23-00 - No phaseTaking peopleMulticenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis
- Where
- Toulouse
- Életkor
- 18 év and over
- People
- 2200 worldwide
- Run by
- Idoven 1903 S.L.
See details and how to joinNCT06978660 - 1. fázisTaking peopleA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Where
- Nantes, Pierre-Bénite, Rennes, Toulouse
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00 - No phaseTaking peopleLongitudinal Quantitative Neuromuscular MRI in Neuropathic Patients
- Where
- Marseille
- Életkor
- 18 év and over
- People
- 120
- Run by
- Assistance Publique Hopitaux De Marseille
See details and how to joinNCT06845644 - 3. fázisCsak meghívásosA Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Where
- Créteil, Marseille, Paris, Rennes, Toulouse
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT06679946 - 3. fázisTaking peopleCLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
- Where
- Amiens, Bron, Chambray-lès-Tours, Créteil, Dijon, La Roche-sur-Yon, La Tronche, Marseille, Metz-Tessy, Montpellier, Nantes, Nice, Paris, Pessac, Poitiers, Rennes, Toulon, Toulouse, Villeurbanne
- Életkor
- 18 év and over
- People
- 1280 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07207811 - 3. fázisTaking peopleTRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
- Where
- Chambray Les Tours, Creteil Cedex, Dijon, Fort De France Cedex, Grenoble Cedex 9, Marseille, Montpellier Cedex 5, Paris, Paris Cedex 18, Pessac, Reims Cedex, Rennes Cedex 9, Rouen Cedex, Saint-Herblain, Strasbourg Cedex, Toulouse Cedex 9
- Életkor
- 18 év to 85 év
- People
- 1750 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00 - No phaseTaking peopleConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
- Where
- Bordeaux, Bron, Créteil, Le Kremlin-Bicêtre, Marseille
- People
- 1500 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT04561518 - No phaseTaking peoplePatisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
- Where
- Nantes
- People
- 10 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT05040373 - 3. fázisTaking peopleTRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
- Where
- Creteil Cedex, Le Kremlin Bicetre Cedex, Marseille
- Életkor
- 18 év to 85 év
- People
- 125 worldwide
- Run by
- Alnylam Pharmaceuticals
See details and how to joinNCT07223203 · EU 2025-522544-40-00 - No phaseTaking peopleImpact of a Cardiac Rehabilitation Program on Patients With Cardiac Amyloidosis
- Where
- Montpellier
- Életkor
- 18 év and over
- People
- 40
- Run by
- University Hospital, Montpellier
See details and how to joinNCT07494942 - No phaseTaking peoplePrevalence of Cardiac Thrombi in Cardiac Amyloidosis
- Where
- Dijon
- Életkor
- 18 év and over
- People
- 200
- Run by
- Centre Hospitalier Universitaire Dijon
See details and how to joinNCT07648303 - No phaseTaking peopleStudy of Acoramidis in Patients With Transthyretin Amyloid Cardiomyopathy
- Where
- Many Locations
- Életkor
- 18 év and over
- People
- 500
- Run by
- Bayer
See details and how to joinNCT07791160 - 2. fázisTaking peopleExploratory Study Evaluating the Relevance of [68Ga]Ga-FAPI-46 for Staging and Identifying Progressing Patients With Transthyretin Cardiac Amyloidosis
- Where
- Nantes Cedex 1
- Életkor
- 18 év and over
- People
- 40
- Run by
- Nantes University Hospital
See details and how to joinNCT07549841 · EU 2025-523616-36-00 - 3. fázisNot yet taking people in FranciaországAn Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
- Where
- Bron, Chambray-lès-Tours, Créteil, Marseille, Montpellier, Paris, Pessac, Poitiers, Rennes, Saint-Herblain, Toulouse
- People
- 1180 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07789483 · EU 2026-526755-57-00 - No phaseTaking peopleAnalysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy
- Where
- Lille
- Életkor
- 18 év and over
- People
- 30
- Run by
- GCS Ramsay Santé pour l'Enseignement et la Recherche
See details and how to joinNCT04849754 - 3. fázisNot yet taking people in FranciaországTo Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
- Where
- Bordeaux, Créteil, Fort De France Cedex, Le Kremlin Bicetre Cedex, Rennes, Toulouse Cedex 9
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT07116473 · EU 2024-513676-18-00 - 3. fázisTaking peopleAcoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
- Where
- Bordeaux, Créteil, Fort De France Cedex, Le Kremlin Bicetre Cedex, Rennes, Toulouse Cedex 9
- Életkor
- 18 év to 75 év
- People
- 587 worldwide
- Run by
- Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895 · EU 2024-513547-82-00 - 2/3. fázisCsak meghívásosLong-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
- Where
- Le Kremlin-Bicetre
- Életkor
- 18 év and over
- People
- 72 worldwide
- Run by
- Intellia Therapeutics
See details and how to joinNCT05697861 · EU 2023-507385-11-00 - No phaseNot yet taking people in FranciaországProspective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion System
- Where
- Pierre-Bénite
- Életkor
- 18 év and over
- People
- 100
- Run by
- Hospices Civils de Lyon
See details and how to joinNCT07721350 - No phaseTaking peopleEvaluation of Skin Tests in Biotherapy Allergies
- Where
- Angers
- Életkor
- 18 év and over
- People
- 70
- Run by
- University Hospital, Angers
See details and how to joinNCT06971848 - No phaseTaking peopleConcordance for Transthyretin Amyloidosis Between Synovial Biopsy and Anterior Carpal Ligament Biopsy
- Where
- Montpellier
- Életkor
- 18 év and over
- People
- 500
- Run by
- Clinique Saint Jean, France
See details and how to joinNCT07644325 - No phaseTaking peoplePrevalence and Significance of ATTR Aortic Valve Amyloidosis in Degenerative Aortic Stenosis
- Where
- Toulouse
- Életkor
- 18 év to 99 év
- People
- 100
- Run by
- University Hospital, Toulouse
See details and how to joinNCT04636684 - 1/2. fázisTaking peopleA Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
- Where
- Limoges Cedex 1, Toulouse Cedex 9
- Életkor
- 18 év and over
- People
- 76 worldwide
- Run by
- AbbVie
See details and how to joinNCT06158854 · EU 2023-503429-20-00